Pharma-Bio Serv, Inc.
PBSV
$0.51
-$0.09-15.00%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.66% | 3.83% | -35.15% | -47.17% | -47.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.66% | 3.83% | -35.15% | -47.17% | -47.90% |
| Cost of Revenue | -9.14% | -7.67% | -39.79% | -41.11% | -45.31% |
| Gross Profit | 32.37% | 43.41% | -21.85% | -59.01% | -54.06% |
| SG&A Expenses | -1.60% | -11.66% | -10.28% | -6.64% | -3.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.53% | -9.05% | -31.85% | -31.99% | -35.67% |
| Operating Income | 68.63% | 78.96% | -197.49% | -182.91% | -182.45% |
| Income Before Tax | 152.39% | 103.76% | 69.04% | -149.40% | -133.63% |
| Income Tax Expenses | -74.06% | -91.47% | -4,328.57% | -68.95% | -87.38% |
| Earnings from Continuing Operations | 144.62% | 103.14% | 134.18% | -158.76% | -152.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 144.62% | 103.14% | 134.18% | -158.76% | -152.83% |
| EBIT | 68.63% | 78.96% | -197.49% | -182.91% | -182.45% |
| EBITDA | 74.18% | 80.79% | -233.78% | -179.93% | -178.31% |
| EPS Basic | 145.16% | 103.39% | 133.33% | -158.95% | -152.84% |
| Normalized Basic EPS | 151.92% | 104.29% | 69.23% | -149.38% | -133.33% |
| EPS Diluted | 143.01% | 103.33% | 133.33% | -161.14% | -152.84% |
| Normalized Diluted EPS | 151.92% | 104.29% | 69.23% | -149.38% | -133.33% |
| Average Basic Shares Outstanding | -0.12% | -0.02% | -0.11% | -0.02% | -0.01% |
| Average Diluted Shares Outstanding | -0.11% | -0.11% | -0.11% | -0.10% | -0.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 3.24% | -- | -- | -- | -2.89% |